Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Women have less significant blockages of coronary arteries, however have greater symptoms and
worse outcomes compared to their age-matched male counterparts. This paradox has led to the
recognition and importance of the microvasculature ( small vessels) as a contributor to
symptoms and outcomes. Nebivolol has unique antioxidant properties and dilates blood vessels
and it is therefore proposed that treatment with nebivolol will reduce angina (chest
symptoms) in women with microvascular disease as well as improve exercise capacity, reduce
resource utilization and improve other measures of artery function.